Arog Pharmaceuticals
AROG
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
-
Biotechnology & Medical Research
2018-09-28
Public Filing
View Prospectus
Pending
Offering
Price Range: Pending
Shares to be Issued: Pending
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 3246.00K
Listed

Buy or sell shares of AROG and other stocks commission-free!

Open a Webull account and fund it to get a free stock

About AROG
Arog Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on developing crenolanib, which is a mutation-resistant type I pan-FLT3 inhibitor for cancer patients. The Company has commenced two pivotal Phase III clinical trials of crenolanib in FLT3-mutated acute myeloid leukemia (AML). The Company has also initiated Phase III clinical trial of CRENOGIST in patients with advanced or metastatic gastrointestinal stromal tumors (GIST) with a specific mutation (DD842V) in the platelet-derived growth factor receptor A (PDGFRA) gene.
More

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

Webull offers kinds of Arog Pharmaceuticals stock information, including NASDAQ:AROG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AROG stock news, and many more online research tools to help you make informed decisions.